News Release
More-
January 21, 2025
Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® in South Korea -
January 14, 2025
Notification of co-promotion agreement termination of Minirin Melt and Desmopressin formulations -
January 7, 2025
Sub-licensing Agreement for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® with Tai Tien Pharmaceuticals in Taiwan -
December 23, 2024
Regarding the approval of the additional indication for endometriosis in Europe for the GnRH antagonist YSELTY® (generic name linzagolix) -
November 6, 2024
Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System (ToSTNeT-3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares
Topics
More-
November 5, 2024
The Second Quarter of FY2024 (November 5, 2024) -
November 5, 2024
R&D Pipeline as of November 2024 -
October 28, 2024
Annual Report 2024 -
October 28, 2024
Financial Data Book 2024 -
July 30, 2024
The First Quarter of FY2024 (July 30, 2024)
